ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma
作者： Didier Roulin , Nicolas Demartines , Olivier Dormond
DOI: 10.1042/BST0390492
关键词:
摘要: Targeting mTOR (mammalian target of rapamycin) is an effective approach in the treatment advanced RCC (renal cell carcinoma). Rapamycin-like drugs (rapalogues) have shown clinical activities and been approved for RCC. Recently, with development ATP-competitive inhibitors mTOR, therapies targeting entered a new era. Here, we discuss biological relevance blocking review mechanisms action rapalogues We also advance some perspectives on use
portlandpress.com
biochemsoctrans.org参考文章(34)
Sébastien Albert, Maria Serova, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre, Eric Raymond, New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opinion on Investigational Drugs. ,vol. 19, pp. 919- 930 ,(2010) , 10.1517/13543784.2010.499121
Alejo Efeyan, David M Sabatini, mTOR and cancer: many loops in one pathway Current Opinion in Cell Biology. ,vol. 22, pp. 169- 176 ,(2010) , 10.1016/J.CEB.2009.10.007
Ker Yu, Celine Shi, Lourdes Toral-Barza, Judy Lucas, Boris Shor, Jae Eun Kim, Wei-Guo Zhang, Robert Mahoney, Christine Gaydos, LuAnna Tardio, Sung Kyoo Kim, Roger Conant, Kevin Curran, Joshua Kaplan, Jeroen Verheijen, Semiramis Ayral-Kaloustian, Tarek S Mansour, Robert T Abraham, Arie Zask, James J Gibbons, None, Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2 Cancer Research. ,vol. 70, pp. 621- 631 ,(2010) , 10.1158/0008-5472.CAN-09-2340
P Cao, S-M Maira, C García-Echeverría, D W Hedley, Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts British Journal of Cancer. ,vol. 100, pp. 1267- 1276 ,(2009) , 10.1038/SJ.BJC.6604995
Dos D Sarbassov, Siraj M Ali, Shomit Sengupta, Joon-Ho Sheen, Peggy P Hsu, Alex F Bagley, Andrew L Markhard, David M Sabatini, None, Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell. ,vol. 22, pp. 159- 168 ,(2006) , 10.1016/J.MOLCEL.2006.03.029
Marija Velickovic, Brett Delahunt, Bryan McIver, Stefan K G Grebe, Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Modern Pathology. ,vol. 15, pp. 479- 485 ,(2002) , 10.1038/MODPATHOL.3880551
William G. Kaelin, Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer. ,vol. 115, pp. 2262- 2272 ,(2009) , 10.1002/CNCR.24232
Othon Iliopoulos, Adam Kibel, Steven Gray, William G. Kaelin, Tumour suppression by the human von Hippel-Lindau gene product. Nature Medicine. ,vol. 1, pp. 822- 826 ,(1995) , 10.1038/NM0895-822
William G Kaelin Jr, None, The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer Nature Reviews Cancer. ,vol. 8, pp. 865- 873 ,(2008) , 10.1038/NRC2502
D. A. Guertin, D. M. Sabatini, The Pharmacology of mTOR Inhibition Science Signaling. ,vol. 2, ,(2009) , 10.1126/SCISIGNAL.267PE24